Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of BCG-unresponsive high-risk non-muscle-invasive bladder cancer
Economic burden and healthcare resource utilization
7 evidence topics · 7 sources
Healthcare resource utilization and costs after BCG in high-grade NMIBC, by progression status
“Patients aged ≥ 65 years diagnosed with HG-NMIBC between 2008 and 2015 who received adequate BCG induction and were identified in the SEER-Medicare database.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of 986 patients diagnosed with HG-NMIBC who met the inclusion criteria, 257 (26.1%) progressed; the mean ages were similar between patients who did and did not progress (77.6 vs. 77.0 years). The overall population had a mean of 0.96 [standard deviation (SD): 1.18] inpatient admissions, 6.47 (11.40) hospitalization days, 1.38 (2.19) emergency department (ED) visits, and 48.03 (44.97) outpatient visits per patient-year during the study period; total annualized costs per patient post-BCG were $39,102 ($44,244).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients experiencing progression had significantly higher mean numbers of inpatient admissions [1.61 (SD 1.40) vs. 0.72 (0.99)], hospitalization days [11.77 (14.96) vs. 4.59 (9.29)], ED visits [2.34 (2.92) vs. 1.03 (1.76)], and outpatient visits [65.97 (44.72) vs. 41.63 (43.09)] per patient-year compared with patients without progression (all p < 0.05). Total mean annualized costs per patient after BCG among those who progressed [$65,668 (SD $53,943)] were more than double compared with patients who did not [$29,780 ($36,425)].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Costs of high-risk NMIBC after BCG in the Veterans Affairs Health System, by progression status
“This retrospective cohort study identified 412 patients with high-risk NMIBC from 63 139 patients diagnosed with bladder cancer who received at least 1 dose of BCG within Department of Veterans Affairs (VA) centers across the US from January 1, 2000, to December 31, 2015.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All-cause expenditures were summarized as medians with corresponding interquartile ranges (IQRs) and adjusted to 2019 USD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Total median costs at 1 year were $29 459 (IQR, $14 991-$52 060); at 2 years, $55 267 (IQR, $28 667-$99 846); and at 5 years, $117 361 (IQR, $59 680-$211 298). Patients with progressive disease had significantly higher median 5-year costs ($232 729 [IQR, $151 321-$341 195] vs $94 879 [IQR, $52 498-$172 631]; P < .001), with outpatient care, pharmacy, and surgery-related costs contributing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs and resource use of radical cystectomy and trimodal therapy in the United States
“Of 1323 patients, 839 underwent RC (median age 71 years; 26.2% female), and 484 received trimodal therapy (median age 75; 26.2% female). Median [IQR] per-patient costs were $70,671 [$55,878-$106,812] for the RC cohort at 90-days follow-up and rose to $211,671 [$138,597-$346,389] by 5-years post-index. For trimodal therapy, total costs were $34,612 [$16,705-$64,263] at 90-days and increased to $274,462 [$186,337-$421,534] by 5-years. At 90-days, median overall visits (inpatient, outpatient, emergency room, or other) were 26 [16-39] for RC and 19 [12-33] for trimodal therapy; overall visits were 163 [119-218] and 186 [144-238] by 5-years, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This analysis reveals that RC costs were primarily driven by inpatient services, particularly inpatient facility costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medicare costs of bladder cancer care by phase of care
| Phase of care | Annualized cancer-attributable medical services cost, bladder cancer (2019 US thousand dollars) |
|---|---|
| Initial (first 12 months after diagnosis) | “$25.4”View highlighted excerpt for this quote |
| Continuing | “$6.1”View highlighted excerpt for this quote |
| End of life, cancer death | “$92.2”View highlighted excerpt for this quote |
| End of life, non-cancer death | “$21.8”View highlighted excerpt for this quote |
National costs of bladder cancer care in the United States, 2015 and projected to 2030
“Cancer sites for which population changes will increase costs more than the average (39%) from 2015 through 2030 are bladder (45%), kidney (54%), leukemia (51%), melanoma (51%), Non-Hodgkin (45%), prostate (46%) and thyroid (55%) cancers (Table 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Year | National cost of bladder cancer care, Medicare Parts A, B, and D (2019 US billion dollars) |
|---|---|
| 2015 | “$8.0”View highlighted excerpt for this quote |
| 2020 | “$9.0”View highlighted excerpt for this quote |
| 2025 | “$10.2”View highlighted excerpt for this quote |
| 2030 | “$11.6”View highlighted excerpt for this quote |
Costs of high-risk NMIBC progressing after BCG: systematic review
“Non-muscle-invasive BCa (NMIBC) incurs significant costs for surveillance and treatment, with costs exceeding $200 000 after 5 yr for high-risk NMIBC patients progressing after bacillus Calmette-Guerin (BCG) treatment (including inpatient, outpatient, and physician service expenses). Muscle-invasive BCa generates substantial costs from radical cystectomy (RC) and neoadjuvant chemotherapy, averaging $30 000-40 000 from surgical costs of RC, with additional expenses in case of complications.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Per-patient and lifetime cost of bladder cancer
“Collectively, this results in bladder cancer having the highest cost of any malignancy when stratified on a per-patient basis [7]. A patient diagnosed with localized bladder cancer from the years 1998-2013 contributed to a lifetime cumulative expenditure of roughly $124,000 to Medicare, which is likely higher today given new treatment regimens and higher costs [8].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote